Dissemination (Meeting Coverage)

In a recent session at the 2025 Winter Clinical meeting in Hawaii, presenters shared how dermatologists can add or alter treatments to improve response.

A study at ASH 2024 found that early progression of disease in mantle cell lymphoma significantly worsens survival, indicating the need for a more nuanced approach to risk stratification.

Research published in JAMA Dermatology indicated that home-based phototherapy was as effective as office-based phototherapy for patients with psoriasis.

Findings from the VISIBLE trial will help address gaps in psoriasis care for patients with skin of color and inform best practices to drive inclusive research.

A curated roundup of what happened at ASH 2024, focused on CLL/SLL – treatment updates, improving QOL, and novel agents.

A study exploring the link between disorders of gut-brain interaction and fibromyalgia severity offers insights into managing this complex condition.

MCL patients with secondary malignancies have significantly shorter survival, particularly due to skin cancers and secondary leukemia.

The ASH Research Collaborative developed the COSMIC study to address the risks severe COVID-19 complications pose to patients with multiple myeloma.

The TELEPROM Psoriasis study highlights how telepharmacy and patient-reported outcomes improve the quality of life for patients with moderate-to-severe psoriasis.

Monoclonal antibody delayed progression to MM, improved PFS, ORR, and OS, and was well tolerated in high-risk SMM, supporting early intervention over monitoring.

Liso-cel shows durable efficacy in R/R CLL/SLL, with extended OS of 43.2 months, high uMRD rates, and consistent safety after nearly two years of follow-up.

Researchers at SABCS 2024 identified disparities and advised that male patients should be educated to recognize and seek care for early signs of breast cancer.

Combining manual therapy with exercise enhances pain relief and disability outcomes for low back pain.

The CLL 12 study found ibrutinib improved global health/physical function without overall survival benefits in early-stage, asymptomatic CLL.

On Tuesday, January 21, 2025, Joel Gelfand, MD, will join a panel of speakers to discuss the changing landscape of psoriasis and psoriatic arthritis.

Is there a session you’d like to see Physician’s Weekly cover at Maui Derm?

On Tuesday January 21, 2025 Julie Harper, MD, will lead a discussion on clinical updates for WINLEVI (clascoterone) Cream 1%.

Luis Sumoza, MD, discusses the BRUIN CLL-321 study presented during the ASH Annual Meeting, highlighting the importance of this research and how it will impact patient care.

This year’s ASH was exceptionally busy, with overlapping sessions, including three back-to-back myeloma talks. Key studies showcased practice-changing findings.

A review of treatments for TP53m MCL found high response rates with targeted and CAR-T therapies but highlighted poor survival, urging innovative strategies.